Efficacy, Pharmacokinetics, Safety, and Tolerability of Flebogamma® 10% DIF, a High-Purity Human Intravenous Immunoglobulin, in Primary Immunodeficiency
- 275 Downloads
Flebogamma® 10% DIF represents an evolution of intravenous immune globulin from the previous 5% product to be administered at higher rates and with smaller infusion volumes. Pathogen safety is enhanced by the combination of multiple methods with different mechanisms of action.
The objective of this study as to evaluate the efficacy, pharmacokinetics, and safety of Flebogamma® 10% DIF for immunoglobulin replacement therapy in primary immunodeficiency diseases (PIDD).
Flebogamma® 10% DIF was administered to 46 subjects with well-defined PIDD at a dose of 300–600 mg/kg every 21–28 days for 12 months.
Serious bacterial infection rate was 0.025/subject/year. Half-life in serum of the administered IgG was approximately 35 days. No serious treatment-related adverse event (AE) occurred in any patient. Most of the potentially treatment-related AEs occurred during the infusion, accounting for 20% of the 601 infusions administered.
Flebogamma® 10% DIF is efficacious and safe, has adequate pharmacokinetic properties, and is well-tolerated for the treatment of PIDD.
KeywordsIntravenous immune globulin Flebogamma® 10% DIF IGIV clinical trial primary immunodeficiency disease nanofiltration
- 3.Outbreak of hepatitis C associated with intravenous immunoglobulin administration—United States, October 1993–June 1994 (1994) MMWR Morb Mortal Wkly Rep 43:505–509Google Scholar
- 15.Vlug A, Nieuwenhuys EJ, van Eijk RV, Geertzen HG, van Houte AJ. Nephelometric measurements of human IgG subclasses and their reference ranges. Ann Biol Clin (Paris). 1994;52:561–7.Google Scholar
- 16.US FDA Compliance program guidance manual. Chapter 42—Blood and blood products inspection of source plasma establishments, brokers, testing laboratories and contractors. http://www.fda.gov/cber/cpg/7342002bld.htm. Accessed 27 December 2008
- 17.Code of Federal Regulations, Title 21, Volume7. CFR21 Part 640. April 1, 2008Google Scholar
- 18.Berger M, Flebogamma® 5% DIF® Investigators. A multicenter, prospective, open label, historically controlled clinical trial to evaluate efficacy and safety in primary immunodeficiency disease patients of Flebogamma 5% DIF®, the next generation of Flebogamma. J Clin Immunol. 2007;27:628–33.CrossRefPubMedGoogle Scholar
- 20.US FDA. Guidance for industry: safety, efficacy and pharmacokinetic studies to support marketing of immune globulin intravenous (human) as replacement therapy for primary immune deficiency. www.fda.gov/cber/gdlns/igivimmuno.htm. Accessed 25 March 2009
- 23.Official Disability Guidelines. http://www.disabilitydurations.com/pr_repmdc.htm. Accessed 25 March 2009
- 24.Centers for Disease Control and Prevention. FastStats. http://www.cdc.gov/nchs/fastats. Accessed 25 March 2009